Harmony Biosciences Holdings Inc

For the period ended Mar 31, 2024. Filed Apr 30, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed Apr 30, 2024

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME


· · Three Months Ended March 31, ·
· 2024 · 2023
Net product revenue	$154,615	$119,126
Cost of product sold	27,484	20,780
Gross profit	127,131	98,346
Operating expenses:
Research and development	22,189	13,289
Sales and marketing	27,233	22,572
General and administrative	25,676	22,062
Total operating expenses	75,098	57,923
Operating income	52,033	40,423
Other (expense) income, net	(141)	2
Interest expense	(4,535)	(5,731)
Interest income	4,428	3,086
Income before income taxes	51,785	37,780
Income tax expense	(13,451)	(8,295)
Net income	$38,334	$29,485
Unrealized (loss) income on investments	(173)	120
Comprehensive income	$38,161	$29,605
EARNINGS PER SHARE:
Basic	$0.68	$0.49
Diluted	$0.67	$0.48
Weighted average number of shares of common stock - basic	56,771,251	59,732,157
Weighted average number of shares of common stock - diluted	57,597,627	61,221,511

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.